Skip to main content
. 2017 Dec 1;83(24):e01882-17. doi: 10.1128/AEM.01882-17

TABLE 2.

Antibiotic susceptibility of P. putida B6-2 and its derivatives

Antibiotic (μg/piece)a Inhibition halo (cm)
B6-2 B6-2ΔsrpABC B6-2ΔttgABC B6-2ΔsrpSΔttgABC
Ampicillin (10) Nob No 1.9 ± 0.1 No
Cefepime (30) 2.6 ± 0.2 2.6 ± 0.2 3.6 ± 0.1 3.0 ± 0.2
Cefotaxime (30) 1.9 ± 0.1 1.8 ± 0.1 3.4 ± 0.1 2.5 ± 0.1
Cefoxitin (30) No No 2.8 ± 0.2 No
Ceftazidime (30) 2.5 ± 0.0 2.3 ± 0.2 2.9 ± 0.2 2.7 ± 0.1
Nalidixic acid (30) 1.8 ± 0.3 1.8 ± 0.2 3.1 ± 0.2 2.4 ± 0.1
Novobiocin (30) No No 1.5 ± 0.0 0.8 ± 0.1
Tetracycline (30) 1.3 ± 0.3 1.3 ± 0.1 2.3 ± 0.1 1.9 ± 0.0
Chloramphenicol (30) No No 1.1 ± 0.1 0.9 ± 0.1
Erythromycin (15) No No 1.5 ± 0.1 2.0 ± 0.0
Gentamicin (10) 1.5 ± 0.1 1.6 ± 0.0 2.2 ± 0.1 2.3 ± 0.1
Meropenem (10) 0.8 ± 0.1 1.0 ± 0.2 2.5 ± 0.2 2.6 ± 0.2
Spectinomycin (100) No No 1.5 ± 0.2 2.5 ± 0.1
Streptomycin (10) No No 2.0 ± 0.1 2.1 ± 0.0
a

Fourteen of the 20 antibiotics tested in this assay are shown. There were no differences found in susceptibility to rifampin, fosfomycin, teicoplanin, nystatin, lincomycin, or polymyxin B.

b

No, no bacteriostatic ring.